Hydreight Technologies Announces Corporate Update Highlighting Q3 Momentum, VSDHOne Acceleration, and 2026 Outlook
Executive Summary
- Hydreight Technologies reported Q3 2025 GAAP revenue of $10.52 M (up 132% YoY) and GAAP net income of $362 K, marking a turnaround from a loss in Q3 2024.
- Adjusted EBITDA reached $620 K and cash on hand grew to $18.64 M, underscoring strong profitability and liquidity.
- The company highlighted rapid expansion of its multi‑vertical platform (including VSDHOne), nurse network growth (+49% YoY Q3 sign‑ups) and a 72% YoY increase in pharmacy order volume, positioning it for continued scaling into 2026.
Key Details
- Q3 2025 Financial Highlights
- GAAP revenue: $10.52 M (↑132% YoY)
- Topline revenue (non‑GAAP): $12.83 M (↑110% YoY)
- Gross margin: $2.33 M (up from $1.53 M in Q3 2024)
- Adjusted EBITDA: $620 K
- GAAP net income: $362 K (vs. a loss of $90 K in Q3 2024)
- Adjusted margin: 28.21%
-
Cash on hand at quarter‑end: $18.64 M
-
First Nine Months 2025
- Topline revenue: $26.71 M (↑61% YoY)
-
GAAP revenue: $20.44 M (↑70% YoY)
-
Multi‑Vertical Platform – GLP‑1 treatments now represent ~28% of activity; other verticals include TRT, peptides, NAD+, hair loss, genetics, sexual‑health products, ondansetron, and additional categories in development.
-
Nurse Network & Clinic Adoption
- 198 new nurse sign‑ups Q3 2025 (↑49% YoY)
-
593 nurse sign‑ups YTD 2025 vs. 364 YTD 2024 (≈63% YoY increase)
-
Pharmacy Volume Growth – Pharmacy orders up ~72% YoY, reflecting repeat usage and broader category adoption.
-
VSDHOne Platform
- Launched late June 2025; modular, 50‑state compliant with physician oversight and integrated pharmacy fulfillment.
- Q3 2025 product orders placed: ≈295,000
- YTD (as of Dec 1 2025) product orders placed: ≈887,000
-
Target for 2025: ~1.3 M product orders placed – on track based on current pace.
-
Operational KPI Clarification – Company will continue using “product orders placed” as its primary metric; acknowledges reconciliation with “orders delivered.”
-
Strategic Ecosystem Development
- Holds a 5% stake in Perfect Scripts (option to increase).
- Evaluating profitable multi‑state operators.
-
Expanding into genetics, NAD+, oral weight‑management categories.
-
Compliance & Infrastructure – Nationwide licensed physicians, state‑by‑state telehealth compliance, integrated 503A/503B pharmacy partners, secure prescribing and fulfillment networks.
-
Margin Model & AOV Drivers – Margins vary by category; multi‑vertical adoption improves blended margins; automation and workflow enhancements expected to boost long‑term efficiency.
-
2026 Framework – Focus on margin discipline, increased automation, stronger onboarding processes, expanded multi‑vertical adoption, reinforced compliance and operational infrastructure.
-
Guidance – Full 2026 guidance slated for release in mid‑December 2025.
Notable Quotes
“We continue to focus on building Hydreight with a structured and deliberate approach… The recent results and platform activity reflect the infrastructure, partnerships, and operational foundation we have put in place over the past several years.” – Shane Madden, CEO
“Our priorities for 2026—automation, onboarding processes, and multi‑vertical support—are based on ongoing analysis of partner behavior and workflow requirements.” – Shane Madden, CEO